FDA Plans To Require Submission Of Overseas Label Changes Under Draft Rule
Executive Summary
FDA is developing a proposed rule that would require pharmaceutical manufacturers to notify the agency of labeling changes that occur overseas, FDA Office of Drug Evaluation V Deputy Director Jonca Bull, MD, indicated during a Dec. 5 House Government Reform Committee hearing.
You may also be interested in...
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
FDA's safety reporting rule would require drug and biologic sponsors to review any safety information acquired from a foreign regulatory authority to determine whether it should be reported to the agency
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
FDA's safety reporting rule would require drug and biologic sponsors to review any safety information acquired from a foreign regulatory authority to determine whether it should be reported to the agency
Accutane Psychiatric Safety Trial Planned: Roche Prepares For Hearings
Roche and FDA are in discussions about the design for a prospective study to resolve questions about a potential link between the acne drug Accutane (isotretinoin) and psychiatric side effects.